The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

Alnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its ...

Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat ...

Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major ...

Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...

Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio.

Redburn Atlantic initiated coverage of Alnylam with a Buy rating and $353 price target Therapeutic options for patients with transthyretin ...

Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report report ...